998TiP GUARDIAN-101: A first in human, tumor agnostic phase I study evaluating safety and preliminary antitumor activity of CLSP-1025, a first in class, HLA-directed T cell engager (TCE) for advanced solid tumors harboring the p53 R175H mutation. - Subbiah, V.; Bashir, B.; El-Khoueiry, A.B.; Punekar, S.; Khawaja, M.R.; Gutierrez, M.; Olszanski, A.J.; Bilusic, M.; Arnold, S.M.; Scott, A.J.; Berlin, J.D.; Oh, D.; et al. (Annals of Oncology, 2025)